Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Clinical Genitourinary Cancer|May 14, 2013
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II TrialJohn D Hainsworth, Mark S Rubin, Edward R Arrowsmith, et al.Melanoma Research|August 24, 2013
Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research ConsortiumRalph J Hauke, Jeffrey R Infante, Mark S Rubin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2012
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research instituteJohn D Hainsworth, Mark S Rubin, David R Spigel, et al.Cancer Investigation|December 9, 2009
Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancerMuhammad W Saif, Nikolai A Podoltsev, Mark S Rubin, et al.Lung Cancer (Amsterdam, Netherlands)|May 8, 2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancerDavid R Spigel, F Anthony Greco, Mark S Rubin, et al.Cancer Biology & Therapy|January 30, 2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trialJeffrey R Infante, Hendrik-Tobias Arkenau, Johanna C Bendell, et al.Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)David R Spigel, Mark S Rubin, Victor G Gian, et al.Cancer|June 22, 2010
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.Pageof 1